|Bid||1,225.60 x 0|
|Ask||1,250.00 x 0|
|Day's range||1,210.80 - 1,247.00|
|52-week range||1,190.80 - 1,772.51|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||10.89|
|Earnings date||28 Apr 2021|
|Forward dividend & yield||0.80 (6.44%)|
|Ex-dividend date||18 Feb 2021|
|1y target est||1,644.50|
Vir Biotechnolgy (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) recently expanded their partnership from a single drug to treat COVID-19 to a multi-drug partnership that covers a drug for the flu, as well as drugs that Vir hasn't even developed yet.
Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.
Johnson & Johnson (NYSE: JNJ) recently won U.S. Emergency Use Authorization (EUA) for its vaccine. In this Motley Fool Live video, recorded on Feb. 24, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not Sanofi and GlaxoSmithKline might be too late to the party.